OUR PRODUCTS
REIMBURSEMENT TO PDD PLAN CONVERSION RISK ASSESSMENT
For Canadian plan sponsors with reimbursement plan designs, deliberating a move to a pay-direct drug (PDD) design can be a daunting challenge. With conflicting messages of anticipated 20% increases through greater plan member utilization of the benefit with the PDD format versus better plan management tools available with the real-time adjudication of PDD plans, it is no wonder that HR professionals have struggled with the pros and cons of such a conversion.
Our Reimbursement to PDD Plan Conversion Risk Assessment has been developed specifically to assist these groups. The report allows HR and their colleagues in Finance/Accounting to answer the risk versus benefit and return-on-investment questions by weighing the specific financial liabilities from the conversion against the potential cost savings available through various mechanisms with PDD adjudication, right down to the dollars and cents.
